Omalizumab therapy was linked to improved inflammatory biomarkers and symptom scores after 16 weeks in patients with severe allergic asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results